Studies have highlighted Nilotinib’s ability to inhibit the proliferation of CML cells through the Bcr-Abl, c-Kit, or platelet-derived growth factor receptor (PDGFR) signaling pathway [44,45]. This evidence concerns the gene PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive.